Bayer shores up contraceptive offering with Conceptus buy
This article was originally published in Clinica
Executive Summary
German firm Bayer has expanded its contraceptive offering by agreeing to purchase device developer Conceptus for $1.1 billion, or $31 per share. The move highlights pharma’s continued appetite for traditional medical devices, even though Clinica recently noted that pharmaceutical players are reluctant to buy into the in vitro diagnostics space (www.clinica.co.uk, 4 April 2013). Bayer expects the deal to close by mid-2013.